Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00212537 · ClinicalTrials.gov registry record
Disease Modifying Genes in Severe Asthma
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 941
- Enrollment target
NCT00212537: Completed study, sponsored by NYU Langone Health.
NCT00212537 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 941 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00212537 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 941 participants
- Enrollment target
Study Summary
Gene and protein bank to study disease modifying and susceptibility genes and proteins in urban patients with asthma.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 941 participants |
| Start Date | 2002-04-08 |
| Est. Completion | 2019-07-23 |
What the finished NCT00212537 record still lists
NCT00212537 is an observational study that tracks outcomes without assigning an intervention. The registered 941 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00212537 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00212537 about?
NCT00212537 is a clinical study titled "Disease Modifying Genes in Severe Asthma". Gene and protein bank to study disease modifying and susceptibility genes and proteins in urban patients with asthma.
What is the current status of trial NCT00212537?
This trial is currently completed. The enrollment target is 941 participants. The study started on 2002-04-08. Estimated completion is 2019-07-23.
Who is sponsoring clinical trial NCT00212537?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- NCT03075696 · 940 participants · Phase 1
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI